Last reviewed · How we verify

Secondary infection of trauma, and burn wounds caused by MRSA — Treatment Landscape & Competitive Intelligence

Secondary infection of trauma, and burn wounds caused by MRSA (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Secondary infection of trauma, and burn wounds caused by MRSA, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Cubicin Daptomycin Baxter lipopeptide antibacterial 2003-01-01
Cubicin Cubicin Clinical Alliance for Research & Education - Infectious Diseases, LLC. Outer membrane porin protein OmpD
DAPT DAPT Baxter Hlthcare Corp Outer membrane porin protein OmpD

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Baxter · 1 drug in Secondary infection of trauma, and burn wounds caused by MRSA
  2. Baxter Hlthcare Corp · 1 drug in Secondary infection of trauma, and burn wounds caused by MRSA
  3. Clinical Alliance for Research & Education - Infectious Diseases, LLC. · 1 drug in Secondary infection of trauma, and burn wounds caused by MRSA

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Secondary infection of trauma, and burn wounds caused by MRSA:

Cite this brief

Drug Landscape (2026). Secondary infection of trauma, and burn wounds caused by MRSA — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/secondary-infection-of-trauma-and-burn-wounds-caused-by-mrsa. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing